Evidence map›Paper›PMID 41134566›Full record

ReviewChemical communications (Cambridge, England)2025

Lipid II unlocked: strategies for obtaining a major antibiotic target.

Luke J Tyrie, Milandip Karak, Stephen A Cochrane

Abstract readReview
In one paragraph

Review in Chemical communications (Cambridge, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Luke J TyrieSchool of Chemistry and Chemical Engineering, Queen's University Belfast, David Keir Building, Stranmillis Road, Belfast, BT9 5AG, UK. m.karak@qub.ac.uk.
Milandip KarakSchool of Chemistry and Chemical Engineering, Queen's University Belfast, David Keir Building, Stranmillis Road, Belfast, BT9 5AG, UK. m.karak@qub.ac.uk.ORCID http://orcid.org/0000-0001-9998-5994
Stephen A CochraneSchool of Chemistry and Chemical Engineering, Queen's University Belfast, David Keir Building, Stranmillis Road, Belfast, BT9 5AG, UK. m.karak@qub.ac.uk.ORCID http://orcid.org/0000-0002-6239-6915

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial resistance (AMR) is a major global concern. It caused nearly five million deaths in 2019 and is projected to be responsible for up to ten million annually by 2050. A deeper understanding of how antibiotics interact with their molecular targets is essential to addressing this threat, as it can facilitate rational drug design. One major antibiotic target is lipid II, a highly conserved and essential precursor in bacterial cell wall biosynthesis. As the final monomeric intermediate in peptidoglycan biosynthesis, lipid II has become an important target for antibiotic discovery. However, accessing lipid II remains technically challenging. In this review, we examine the three main strategies used to obtain lipid II: direct extraction from bacteria, enzymatic or chemoenzymatic assembly using purified or partially purified biosynthetic machinery, and total chemical synthesis. We discuss the strengths and limitations of each method, scalability, and structural control, and highlight notable approaches that are expanding the accessibility of lipid II and its analogues. These advances are critical not only for antibiotic research but also for understanding bacterial physiology at the molecular level.

Indexed as

Anti-Bacterial AgentsUridine Diphosphate N-Acetylmuramic AcidBacteriaAnti-Bacterial Agentsmuramyl-NAc-(pentapeptide)pyrophosphoryl-undecaprenolUridine Diphosphate N-Acetylmuramic Acid

Identifiers

PMID41134566
PMCPMC12560707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.